



THE PRESCRIBER e-LETTER

Overview of More Restrictive Coverage Changes Effective February 18, 2025

MassHealth evaluates the prior authorization (PA) status for drugs on an ongoing basis and updates the MassHealth Drug List accordingly. The list below outlines changes to the MassHealth Drug List for the rollout effective February 18, 2025, that have been identified as more restrictive in nature.

Change in Prior Authorization Status

Effective February 18, 2025, the following cardiovascular agents will require **PA**.

- Accupril (quinapril) – **PA**; M90
- Accuretic (quinapril/hydrochlorothiazide) – **PA**; M90
- digoxin 62.5 mcg tablet, solution – **PA**; M90
- furosemide solution – **PA**; M90

Effective February 18, 2025, the following topical immunosuppressive agent will require **PA**.

- Elidel (pimecrolimus) – **PA**; A90

Change in MassHealth Brand Name Preferred Over Generic Drug List Status

Effective February 18, 2025, the following agents will be removed from the MassHealth Brand Name Preferred Over Generic Drug List.

- Elidel (pimecrolimus) – **PA**; A90
- Valcyte (valganciclovir powder for oral solution) – **PA**; A90

Deletions

The following drugs will be removed from the MassHealth Drug List effective February 18, 2025, because they have been discontinued by the manufacturer.

- Calan SR (verapamil sustained-release); #, M90
- Comtan (entacapone); A90
- Maxzide (hydrochlorothiazide/triamterene); #, M90
- Menactra (quadrivalent meningococcal conjugate vaccine); 1
- Minipress (prazosin) – **PA** < 6 years; #, M90
- Mirapex (pramipexole); A90
- Rythmol SR (propafenone extended-release); # M90
- Stalevo (carbidopa/levodopa/entacapone); A90

- Symjepi (epinephrine injection)
- Tekturna HCT (aliskiren/hydrochlorothiazide)
- Verelan PM (verapamil extended-release); #, M90
- Ziac (bisoprolol/hydrochlorothiazide); #, M90

On February 10, 2025, the [MassHealth Drug List's Upcoming and Recent Updates](#) page will contain a summary of changes that will become effective on February 18, 2025. Please refer to the updated summary for more information (including other important upcoming changes). Additional information about coverage status and Prior Authorization requirements can be found on the [MassHealth Drug List website](#).

The Prescriber e-Letter is an update designed to enhance the transparency and efficiency of the MassHealth drug prior-authorization (PA) process and the MassHealth Drug List. Each issue highlights key clinical information and updates to the MassHealth Drug List. The Prescriber E-Letter was prepared by the MassHealth Drug Utilization Review Program and the MassHealth Pharmacy Program.